Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 28, 2012, and provides historical quarterly restated financial information for the year ended December 31, 2011, and comparative periods. The filing announces significant changes to segment reporting effective Q1 2012, including the creation of a new "Emerging Markets/Asia Pacific" (EMAP) segment and the reclassification of certain OTC dermatology brands from Pharmaceuticals to Consumer Healthcare. Additionally, GSK introduced "core measures" for operating profit and earnings per share to exclude volatility from intangible asset impairments, legal charges, and restructuring costs.
Key Financial Metrics (Year Ended Dec 31, 2011)
| Metric | Total Results (Restated) | Core Results |
|---|---|---|
| Turnover | £27,387 million | £27,387 million |
| Operating Profit | £7,807 million | £8,803 million |
| Profit Before Taxation | £7,698 million | £8,111 million |
| Profit After Taxation | £5,458 million | £6,007 million |
| Profit Attributable to Shareholders | £5,261 million | £5,810 million |
| Earnings Per Share (EPS) | 104.6p | 115.5p |
| Effective Tax Rate | 29.1% | 25.9% |
Pharmaceuticals and Vaccines Turnover (12 months ended Dec 31, 2011): £22,112 million (CER growth -4%).
Consumer Healthcare Turnover (12 months ended Dec 31, 2011): £5,275 million (CER growth +5%).
Material Changes vs. Prior Period
- Reporting Structure: The company consolidated Emerging Markets and Asia Pacific into a single EMAP segment. Australasia was moved to "Rest of World." Product classifications were updated, including the creation of a "Rare diseases" therapy area and the transfer of Zovirax to Anti-virals.
- Accounting Presentation: Amortisation and impairment of intangible assets related to marketed products are now reported in cost of sales rather than SG&A.
- Performance Trends: Total turnover decreased slightly from £28,392 million in 2010 to £27,387 million in 2011. However, Core Operating Profit increased significantly from £9,497 million in 2010 to £8,803 million in 2011, driven largely by the removal of a £4,001 million legal charge and £1,345 million in restructuring costs recorded in 2010.
- Product Performance: Respiratory products (led by Seretide/Advair) remained the largest revenue generator at £7,298 million. Vaccines saw a decline of 19% in CER growth, while Consumer Healthcare grew 5% in CER terms.
Guidance, Outlook, and Risks
The filing does not provide specific forward-looking financial guidance or numerical targets for future periods. Management commentary focuses on the adoption of core measures to provide a clearer view of underlying business performance by removing one-off items such as legal charges and asset disposal gains/losses. The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in the company's Annual Report on Form 20-F for 2011.
Investor Verification Checklist
- Core vs. GAAP Reconciliation: Verify the specific adjustments made to arrive at "Core" earnings, particularly the £441 million intangible amortisation and £590 million major restructuring costs excluded in 2011.
- Segment Comparability: Review the restated historical data provided in the filing to ensure accurate year-over-year comparisons given the new EMAP segment definition.
- Product Lifecycle: Monitor the performance of key brands like Seretide/Advair (flat CER growth) and Avandia (significant decline of 71% CER) to assess portfolio sustainability.
- Legal and Restructuring Exposure: Assess the likelihood of future "non-core" charges, as the 2010 results were heavily impacted by a £4,001 million legal charge which is absent in 2011.